Trial Profile

Phase II Trial Evaluating the Immunogenicity and Safety of Ad26.COV2.S Vaccine in Adult Participants in Mali

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad26.COV2 S (Primary) ; COVID-19 vaccine adjuvanted Novavax (Primary) ; Matrix M
Indications COVID 2019 infections
Focus Therapeutic Use
Acronyms CoviCompMali

Most Recent Events

26 Mar 2024 Planned End Date changed from 1 Jul 2024 to 1 Mar 2025.
26 Mar 2024 Status changed from not yet recruiting to active, no longer recruiting.
14 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com